David R. Nelson
#161,738
Most Influential Person Now
Researcher ORCID ID = 0000-0001-6344-8548
David R. Nelson's AcademicInfluence.com Rankings
Download Badge
Physics
Why Is David R. Nelson Influential?
(Suggest an Edit or Addition)David R. Nelson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. (2014) (1329)
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. (2014) (1202)
- An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011) (1152)
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (2013) (1122)
- Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (934)
- Response-guided telaprevir combination treatment for hepatitis C virus infection. (2011) (799)
- All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015) (676)
- Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. (2007) (622)
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (2015) (621)
- An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection (2004) (511)
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. (2017) (484)
- Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. (2000) (363)
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. (2013) (341)
- The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. (1997) (333)
- Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment (2017) (324)
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial (2013) (315)
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. (2017) (300)
- Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. (2014) (268)
- Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function (2016) (267)
- Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect (2003) (214)
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. (2018) (210)
- Review article: the management of hepatocellular carcinoma (2010) (210)
- Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. (2016) (206)
- Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. (2014) (200)
- Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. (2016) (178)
- A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients (2005) (173)
- Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. (2015) (171)
- Clinical pharmacogenetics implementation: Approaches, successes, and challenges (2014) (170)
- Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid (2011) (159)
- Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation (2006) (157)
- Activation of Tumor Necrosis Factor-α System in Chronic Hepatitis C Virus Infection (1997) (151)
- Intrahepatic hepatitis C virus–specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C (1998) (148)
- One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection (2004) (147)
- Anti–Interleukin‐2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation (2001) (144)
- Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C (2004) (138)
- Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study (2017) (134)
- Liver transplantation for hepatocellular carcinoma. (2001) (121)
- Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. (1995) (121)
- Endothelial activation and development of coronary artery disease in transplanted human hearts. (1997) (120)
- Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. (1997) (116)
- PHOENIX: A randomized controlled trial of peginterferon alfa‐2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus (2011) (114)
- Final results of a double‐blind, placebo‐controlled trial of the antifibrotic efficacy of interferon‐γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis (2007) (113)
- Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line (2003) (113)
- C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study (2002) (112)
- Kinase Inhibitor Sorafenib Modulates Immunosuppressive Cell Populations in a Murine Liver Cancer Model (2011) (112)
- Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. (2019) (111)
- Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network (2015) (110)
- Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma (2013) (109)
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. (2013) (109)
- Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. (1997) (107)
- Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. (2014) (105)
- Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. (2007) (104)
- R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin (2008) (103)
- Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C (2002) (100)
- The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma (2011) (100)
- Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma (2013) (100)
- Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). (2014) (99)
- Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. (2015) (98)
- Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. (2012) (97)
- Transforming growth factor‐ß1 in chronic hepatitis C (1997) (95)
- The natural history of hepatitis C cirrhosis after liver transplantation (2009) (95)
- Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens (2014) (88)
- L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. (2016) (85)
- Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3 (2011) (85)
- Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin (2010) (84)
- Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease (2004) (84)
- Short recovery time after percutaneous liver biopsy: should we change our current practices? (2005) (81)
- Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin (2008) (80)
- Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS (2014) (80)
- Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication (2005) (79)
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens (2014) (79)
- 66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS (2008) (79)
- Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. (2013) (79)
- Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. (2006) (78)
- Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency. (2012) (76)
- Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study (2016) (75)
- Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. (2017) (74)
- Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells (2007) (74)
- Management of viral hepatitis in hematologic malignancies. (2008) (73)
- Tobacco use before and after liver transplantation: A single center survey and implications for clinical practice and research (2004) (73)
- Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. (2000) (70)
- DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. (2020) (69)
- Transforming growth factor-beta 1 in chronic hepatitis C. (1997) (67)
- Neutrophil–lymphocyte ratio predicts overall and recurrence‐free survival after liver transplantation for hepatocellular carcinoma (2013) (67)
- Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. (2008) (67)
- Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD (2017) (66)
- Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C (2005) (66)
- Reconstitution of hepatitis C virus–specific T‐cell–mediated immunity after liver transplantation (2005) (65)
- 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3 (2012) (65)
- Ribavirin: current role in the optimal clinical management of chronic hepatitis C. (2009) (64)
- OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma (2013) (63)
- 845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY (2013) (63)
- Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. (1998) (61)
- 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY (2013) (60)
- Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. (2013) (60)
- 1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) (2013) (60)
- Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection (2003) (58)
- Daclatasvir plus sofosbuvir for HCV infection. (2014) (58)
- Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients (2009) (58)
- A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy (2006) (57)
- Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. (2007) (56)
- New therapeutic strategies in HCV: second‐generation protease inhibitors (2013) (55)
- Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. (1999) (55)
- Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. (2010) (54)
- Patient-Reported Immunosuppression Nonadherence 6 to 24 Months after Liver Transplant: Association with Pretransplant Psychosocial Factors and Perceptions of Health Status Change (2013) (54)
- OneFlorida Clinical Research Consortium: Linking a Clinical and Translational Science Institute With a Community-Based Distributive Medical Education Model (2017) (54)
- Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. (2001) (53)
- Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells (2007) (53)
- Institutional profile: University of Florida Health Personalized Medicine Program. (2017) (53)
- The Use of Cyclosporine for Recurrent Hepatitis C After Liver Transplant: A Randomized Pilot Study (2009) (52)
- Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. (2007) (52)
- Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. (2011) (51)
- CD8+ T‐cell interaction with HCV replicon cells: Evidence for both cytokine‐ and cell‐mediated antiviral activity (2003) (51)
- A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment‐naïve patients with chronic hepatitis C: ViSER1 results (2009) (50)
- Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. (2012) (50)
- All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database (2017) (50)
- Viral hepatitis: manifestations and management strategy. (2006) (50)
- Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. (2005) (49)
- Clinical and financial impact of obesity on the outcome of liver transplantation. (2006) (48)
- LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target (2015) (48)
- Iron Regulator Hepcidin Exhibits Antiviral Activity against Hepatitis C Virus (2012) (48)
- 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
- Erratum: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 45 chronic kidney disease (the C-SURFER study): A combination phase 3 study. (Lancet (2015) 386 (1537-45)) (2015) (46)
- Different radiosensitivity of CD4+CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro (2011) (45)
- Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. (2009) (43)
- Direct-acting antiviral agents and the path to interferon independence. (2014) (43)
- Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection (2001) (43)
- 61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3 (2011) (42)
- Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. (2012) (41)
- Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. (2016) (41)
- O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience (2015) (38)
- Characterization of HCV Interactions with Toll-Like Receptors and RIG-I in Liver Cells (2011) (37)
- Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma (2010) (37)
- Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years' experience from a single tertiary medical center. (2008) (37)
- Stabilized β-catenin promotes hepatocyte proliferation and inhibits TNFα-induced apoptosis (2004) (37)
- Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States (2019) (35)
- Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25) (2010) (35)
- Pathogenesis of chronic hepatitis C virus infection. (1998) (33)
- Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013–2015 (2018) (33)
- The Financial Burden of Transplantation: A Single-Center Survey of Liver and Kidney Transplant Recipients (2007) (33)
- LP02 : C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease (2015) (32)
- Proceedings of the 8th Annual Conference on the Science of Dissemination and Implementation (2016) (32)
- A brief psychological intervention to improve adherence following transplantation. (2005) (32)
- Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study. (2019) (31)
- Designing a CTSA‐Based Social Network Intervention to Foster Cross‐Disciplinary Team Science (2015) (30)
- 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (30)
- The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients (2011) (30)
- Liver retransplantation: a single-center outcome and financial analysis. (2005) (30)
- α-Glutathione S-Transferase as a Marker of Hepatocellular Damage in Chronic Hepatitis C Virus Infection (1995) (30)
- Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C (2019) (30)
- Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir (2015) (29)
- The anti‐viral effect of sorafenib in hepatitis C‐related hepatocellular carcinoma (2013) (29)
- Fatigue and sleep quality before and after liver transplantation. (2010) (29)
- Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. (1995) (28)
- 1363 VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS (2011) (28)
- Development of sofosbuvir for the treatment of hepatitis C virus infection (2015) (28)
- Vascular antithrombin and clinical outcome in heart transplant patients. (2001) (27)
- A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. (2006) (27)
- The immunopathogenesis of hepatitis C virus infection. (2001) (27)
- Future options for the management of hepatitis C. (1999) (27)
- 1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY? (2012) (26)
- 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
- Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy. (2019) (26)
- Hepatitis B reactivation and rituximab in the oncology practice. (2010) (25)
- Current and future hepatitis C therapies. (2007) (25)
- Is Early Recurrence of Hepatitis C Associated With Biliary Anastomotic Stricture After Liver Transplantation? (2007) (25)
- High relapse rate seen at week 72 for patients treated with R1626 combination therapy (2008) (24)
- Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. (2018) (23)
- Anti‐hepatitis C virus activity of albinterferon alfa‐2b in cell culture (2007) (23)
- 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY (2011) (23)
- A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma (2009) (23)
- The utility of noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. (1999) (22)
- Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. (1995) (22)
- 479 Moved to parallel session 7 safety and efficacy of viramidine in combination with pegylated interferon alfa-2A for treatment of hepatitis C in therapy-naïve patients (2004) (22)
- The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C (2012) (22)
- A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study (2018) (22)
- On‐treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3–infected patients treated with daclatasvir and sofosbuvir (2016) (22)
- New therapies in the management of hepatitis C virus (2010) (21)
- Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
- A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. (2017) (21)
- Unexpected Maintenance of Hepatitis C Viral Diversity following Liver Transplantation (2012) (21)
- CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant (2013) (21)
- 881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS (2013) (21)
- Hepatitis C drug development at a crossroads (2009) (20)
- 95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS (2009) (20)
- Serum cardiac troponin-T concentrations predict development of coronary artery disease in heart transplant patients. (1998) (20)
- Non-immunologic vascular failure of the transplanted heart. (2003) (19)
- 113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection (2006) (19)
- Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (2018) (18)
- Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis (2018) (18)
- Hepatitis C virus modulates human monocyte‐derived dendritic cells (2010) (18)
- Optimal interferon‐free therapy in treatment‐experienced chronic hepatitis C patients (2015) (17)
- Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. (2004) (17)
- Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care? (2008) (16)
- Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation (2006) (16)
- Coronary artery disease in cardiac allografts: association with arterial antithrombin. (1995) (16)
- Is Model for End-Stage Liver Disease Score Associated with Quality of Life after Liver Transplantation? (2011) (15)
- Modulation of Interferon-Specific Gene Expression by Albumin-Interferon-α in Interferon-α-Experienced Patients with Chronic Hepatitis C (2006) (15)
- Increased vascular endothelial growth factor expression in human hearts with microvascular fibrin. (2001) (15)
- Betaine Resolves Severe Alcohol-Induced Hepatitis and Steatosis Following Liver Transplantation (2006) (15)
- Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients (2013) (15)
- 1042 Efficacy and Safety Results of Albinterferon Alfa-2b in Combination With Ribavirin in Interferon-Alfa Treatment Naive Patients With Genotype 2 or 3 Chronic Hepatitis C (2009) (14)
- Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. (2017) (14)
- Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation (2012) (13)
- University of Florida Clinical and Translational Science Institute: Transformation and Translation in Personalized Medicine (2011) (13)
- Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. (2019) (13)
- Hepatic mucormycosis in a renal transplant recipient. (2005) (13)
- Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. (2017) (13)
- Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. (2017) (12)
- Is sonographic surveillance of polytetrafluoroethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary? A single centre experience comparing both types of stents. (2008) (12)
- 12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS (2012) (12)
- Acute Alcoholic Hepatitis (2017) (12)
- Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. (2006) (11)
- P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study (2015) (11)
- Characterization of adult obesity in Florida using the OneFlorida clinical research consortium (2018) (11)
- 61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL (2013) (11)
- 7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3 (2012) (11)
- 6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL (2013) (11)
- Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008 (2012) (11)
- Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals (2019) (11)
- Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. (2015) (11)
- Reactive Oxygen Species Is Essential for Cycloheximide to Sensitize Lexatumumab-Induced Apoptosis in Hepatocellular Carcinoma Cells (2011) (10)
- Fatigue and Sleep Quality before and after Liver Transplantation (2010) (9)
- Abstract 11802: Clinical Implementation Of CYP2C19-genotype Guided Antiplatelet Therapy Reduces Cardiovascular Events After PCI (2015) (9)
- EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (2017) (9)
- Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis (2019) (9)
- Novel interferons for treatment of hepatitis C virus. (2009) (9)
- Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity (2015) (9)
- Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. (2012) (9)
- Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-NaïVE Patients Regardless of Race or Ethnicity (2011) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- P1222 A PHASE II STUDY OF SAMATASVIR (IDX719) IN COMBINATION WITH SIMEPREVIR AND RIBAVIRIN IN TREATMENT-NAÏVE HCV-INFECTED SUBJECTS WITH GENOTYPES 1B AND 4 (HELIX-1 STUDY) (2014) (8)
- Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges (2019) (8)
- Evaluating the efficacy of a registry linked to a consent to re-contact program and communication strategies for recruiting and enrolling participants into clinical trials (2017) (8)
- Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C (2020) (8)
- Tubular antithrombin at transplantation determines subsequent renal allograft function. (1998) (8)
- P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study (2015) (8)
- Immunohistochemical Model to Predict Risk for Coronary Artery Disease and Failure in Heart Transplant Patients (2001) (8)
- alpha-Glutathione S-transferase as a marker of hepatocellular damage in chronic hepatitis C virus infection. (1995) (8)
- Variations of hepatitis C virus NS5B sequence (nucleotides 8261–8566) do not correlate with response to interferon‐α therapy (1995) (8)
- Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience (2011) (7)
- Using Instructional Design to Support Community Engagement in Clinical and Translational Research: a Design and Development Case (2018) (7)
- Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells (2016) (7)
- Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Analysis (2016) (7)
- Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis (2006) (6)
- 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS (2010) (6)
- 1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS (2012) (6)
- Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: Results from the PROP UP study (2021) (6)
- Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
- Coronary artery disease in cardiac allografts: association with depleted arteriolar tissue plasminogen activator. (1995) (6)
- Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells (2011) (6)
- 1016 All-Oral 12-Week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Treatment-Experienced Patients Infected With HCV Genotype (GT) 3: A Subanalysis of the Ally-3 Phase 3 Study (2015) (5)
- ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials (2014) (5)
- 818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR (2013) (5)
- 475 SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naïve Adults With Hepatitis C Virus Genotype 1 (2014) (5)
- Elevated neuropeptide levels decrease during liver transplant. (1993) (5)
- Argininosuccinate synthase as a novel biomarker for inflammatory conditions (2013) (5)
- Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis (2022) (5)
- 456 Safety, pharmacokinetics and pharmacodynamic results of higher doses of albuferon in a phase single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C (2004) (5)
- HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017. (2020) (5)
- Patterns of medication use in the one year following initiation of DPP-4 inhibitors in the United States (2014) (4)
- 956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study (2019) (4)
- 984 Molecular profiles of drug response in HCV infected patients during the first 4 weeks of therapy for chronic hepatitis C virus with pegylated interferon containing regimens or albuferon (2003) (4)
- Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study (2017) (4)
- The Impact of Direct‐Acting Antiviral Therapy on End‐Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders (2021) (4)
- Safety and Efficacy of New Daa Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-Target Study (2016) (4)
- HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape (2015) (4)
- Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research Consortium. (2019) (4)
- 313 A 1/2phase study to evaluate the pharmacokinetics, safety, tolerability, immunogenicity, and pharmacodynamics of albuferon™ in the treatment experienced subjects with chronic hepatitis C (2003) (4)
- Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir (2016) (4)
- Pragmatic trial of a Study Navigator Model (NAU) vs. Ambassador Model (N+) to increase enrollment to health research among community members who use illicit drugs. (2017) (4)
- 890 ALT ABNORMALITIES IN ADULTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY (2011) (4)
- Hepatitis C virus: how to provide the best treatment with what I have (2016) (4)
- 415 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN INCREASED SUSTAINED VIROLOGIC RESPONSE RATES IN TREATMENT-NAIVE PATIENTS REGARDLESS OF RACE OR ETHNICITY (2011) (4)
- Changes in B‐lymphocyte stimulator protein levels during treatment with albinterferon alfa‐2b in patients with chronic hepatitis C who have failed previous interferon therapy (2009) (3)
- Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. (2010) (3)
- Is Interferon Therapy for Hepatitis C Infection a Treatable Risk Factor for Parkinson Disease? (2019) (3)
- A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (2021) (3)
- A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy (2018) (3)
- Transfusion has no effect on recurrence in hepatitis C after liver transplantation (2010) (3)
- Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients (2011) (3)
- THU-181-Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study (2019) (3)
- Audience segmentation as a strategy for enhancing the use of research registries for recruiting patients into clinical trials (2019) (3)
- Incidence of and predictors for direct acting antiviral treatment failure among 3909 hepatitis C genotype 1 infected adults: real world outcomes from HCV TARGET (2017) (3)
- High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence (2021) (3)
- Twice Daily Dosing of Telaprevir for Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Infection (2014) (3)
- HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection (2016) (2)
- Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". (2019) (2)
- Interferon alfa and ribavirin for orthotopic liver transplant recipients with recurrent hepatitis C (2000) (2)
- P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study (2015) (2)
- Treatment Effect and Resistance Profiles were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination Regimen (2011) (2)
- LIVER RE-TRANSPLANTATION: A SINGLE CENTER OUTCOME AND FINANCIAL ANALYSIS (2004) (2)
- Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6: 412 (2013) (2)
- Treatment of chronic hepatitis C. (1997) (2)
- Letters to the Editor: Interleukin-12 production in chronic hepatitis C infection (2000) (2)
- Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data (2021) (2)
- Anti-GOR in chronic HCV patients with membranoproliferative glomerulonephritis. (1996) (2)
- Proteome-wide Analysis and CXCL4 in Systemic Sclerosis (2014) (2)
- Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1 (2015) (2)
- 748 United States Multicenter Study of Ultrasonic TRANSIENT ELASTOGRAPHY (FibroScan) for the Diagnosis of Cirrhosis and Fibrosis in Patients with Hepatitis B and C (2009) (2)
- Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model (2013) (2)
- THE STATUS OF MICROVASCULAR ANTITHROMBIN AFTER EARLY FIBRIN DEPOSITION IS ASSOCIATED WITH OUTCOME IN CARDIAC TRANSPLANT RECIPIENTS. (1998) (2)
- FP267C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE (2015) (1)
- [648] CHARACTERISATION OF HCV GENOTYPE 2/3 PATIENTS WITHOUT A RAPID VIROLOGICAL RESPONSE (RVR): OPTIMISING TREATMENT BY PREDICTING SLOWER RESPONDERS TO PEGINTERFERON a-2a (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) (2007) (1)
- Safety and efficacy of elbasvir and grazoprevir with or without ribavirin for the treatment of hepatitis C virus genotype 1: results of the hepatitis C virus-TARGET study (2017) (1)
- the Impact Of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation : 2 (2010) (1)
- 410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS (2011) (1)
- Incidentally Discovered HCC (iHCC) in Explant Liver-Histopathologic Features and Clinical Outcome (2013) (1)
- P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS (2014) (1)
- Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir. (2021) (1)
- THU-182-The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders (2019) (1)
- P1114 PATIENT-REPORTED OUTCOMES (PROS) IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS TREATED WITH SOFOSBUVIR (SOF) CONTAINING REGIMENS (2014) (1)
- Pathogenesis of recurrent hepatitis C after liver transplantation (2005) (1)
- 537 A SUSTAINED VIRAL RESPONSE DRAMATICALLY IMPROVES SURVIVAL IN PATIENTS WITH HEPATITIS C INFECTION AFTER LIVER TRANSPLANT (2011) (1)
- Determination of HCV-Specific Bulk CD8(+) Activity in Liver. (1999) (1)
- THE CLINICAL EFFICACY OF FUNGAL PROPHYLAXIS IN HIGH RISK LIVER TRANSPLANT RECIPIENTS. (2006) (1)
- Combination of transarterial therapy with sorafenib for hepatocellular carcinoma. (2011) (1)
- Interleukin-1β and risk of coronary artery disease in heart transplant patients (2002) (1)
- Prevalence and Predictors of Immunosuppression Nonadherence Following Liver Transplantation: 591 (2012) (1)
- HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon (2014) (1)
- An immunomodulatory role for CD4+ CD25+ T lymphocytes in hepatitis C infection (2003) (1)
- Interleukin-12 production in chronic hepatitis C infection. (2000) (1)
- Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
- Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis (2019) (1)
- Serum levels of soluble CD 25 as a marker for hepatocellular carcinoma (1)
- Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort (2018) (0)
- 1 THE NATURAL HISTORY OF HCV-RELATED CIRRHOSIS AFTER LIVER TRANSPLANTATION (2008) (0)
- 269 DYNAMICS OF APOPTOTIC ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH ALBINTERFERON ALFA-2B OR PEGINTERFERON ALFA-2A (2010) (0)
- Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial (2022) (0)
- EARLY RISK FACTORS FOR TRANSPLANT CORONARY ARTERY DISEASE.: Abstract# 39 (2000) (0)
- 40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY (2005) (0)
- The soluble form of the IL-2 receptor (sCD25) as a novel biomarker for hepatocellular carcinoma. (2011) (0)
- 2.P.364 Myocardial fibrin deposits in first month after transplantation predict subsequent coronary artery disease in cardiac allograft recipients (1997) (0)
- RECIPIENT RISK FACTORS ASSOCIATED WITH EARLY ABNORMAL MICROVASCULAR CHANGES IN CARDIAC TRANSPLANT PATIENTS (1999) (0)
- Polygenic risk score analysis suggests that iron deficiency does not share genetic risk with Tourette syndrome (2020) (0)
- Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1 (2015) (0)
- 299 BASELINE CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF RIBAVIRIN >800 MG/DAY AMONG G2/3 PATIENTS PRESCRIBED PEGINTERFERON ALFA-2A (40KD) FROM REAL-WORLD PATIENT COHORTS: INTERIM RESULTS FROM PROPHESYS (2010) (0)
- Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection: 868 (2017) (0)
- TLR3 Reduces Hepatitis C Viral Replication in Human Hepatocytes (136.7) (2010) (0)
- Abstract 2702: Sorafenib modulates immune responses in patients with hepatocellular carcinoma (2011) (0)
- National Trends in the Prevalence of Thrombocytopenia Among Individuals Infected With Hepatitis C Virus, 1999 – 2008 (2011) (0)
- Su2054 Relationship Between Model for End-Stage Liver Disease (MELD) Score at the Time of Initial Diagnosis and Survival After Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (2012) (0)
- 834 ANTIVIRAL ACTIVITY AND CHANGES IN B-LYMPHOCYTE STIMULATOR PROTEIN LEVELS DURING TREATMENT WITH ALBINTERFERON ALFA-2B/RIBAVIRIN IN PRIOR INTERFERON-THERAPY NONRESPONDERS (2008) (0)
- 626 CD4+ CD25+ regulatory T lymphocytes respond directly to HCV antigens via cytokine release and suppress HCV-specific T cell responses (2003) (0)
- STAT-C: New therapies cannot get here fast enough (2009) (0)
- HBV reactivation after HCV eradication: Deja Vu (2017) (0)
- Assessing the Safety of Direct-Acting Antivirals for Hepatitis C—A PCORnet Study (2020) (0)
- T2005 Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B or Peginterferon Alfa-2a (2010) (0)
- Health-Related Quality of Life (HRQL) in Chronic Hepatitis C (CH-C) Patients Treated with Sofosbuvir Containing Interferon-Free Regimens (2013) (0)
- Abstract P151: Primary ASCVD Risk Associated With Undiagnosed Conditions Decreased Over NHANES 1999-2014 (2018) (0)
- SERUM CONCENTRATION OF SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 AND RISKS OF FUTURE CORONARY ARTERY DISEASE OF GRAFT FAILURE IN HEART TRANSPLANT RECIPIENTS (1999) (0)
- Tu1013 On-Treatment HCV RNA As a Predictor of Sustained Virologie Response in HCV Genotype 3 - Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of Phase 3 Ally-3 Study (2015) (0)
- An Update on Treatment of Hepatitis C Virus Genotype 1 Infection and Viral Load Assessments To the (2012) (0)
- Tu1573 – Transient Elastography Accurately Predicts Advanced Fibrosis (F3-F4) in Nafld Patients: is It Time to Move Away from Liver Biopsy? (2019) (0)
- Real-World Evidence and Hepatitis C (2019) (0)
- Cardiac-specific troponin I and development of coronary artery disease in heart transplant recipients (2000) (0)
- 358 HEPATOCELLULAR CARCINOMA IS ASSOCIATED WITH AN IMPAIRED CD4 T CELL IMMUNE RESPONSE (2008) (0)
- PSY71 HEALTH AND FUNCTIONAL STATUS FOR INDIVIDUALS WITH THROMBOCYTOPENIA IN THE UNITED STATES: EVIDENCE FROM NHANES (2011) (0)
- Chapter Forty-Four – Long-term care of the liver transplant recipient (2006) (0)
- Treatment Outcomes and Prognostic Factors for Intrahepatic Cholangiocarcinoma Single Center Experience (2011) (0)
- Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection. (1997) (0)
- M1808 Inhibition of Hepatitis C Viral (HCV) Replication By In Vitro Dimerization of IFN Regulatory Factor-3 (IRF3) (2009) (0)
- Comparing Oral Medicines to Treat Hepatitis C Virus -- The PRIORITIZE Study (2022) (0)
- Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (2018) (0)
- O‐28: Safety and efficacy of ledipasvir/sofosbuvir for the treatment of hepatitis c infection: interim analysis of a prospective, observational study (2015) (0)
- HBV3 O‐29: A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B (NCT01732224) (2015) (0)
- Safety of Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir with or without rivavirin in HCV Genotype 1-infected Patients : Results from Phase 2 a,d 3 Trails (2015) (0)
- Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008 (2012) (0)
- M1879 MELD Score Predicts 3-Month Mortality in Hepatitis C Liver Transplant Patients with Recurrent Graft Cirrhosis (2008) (0)
- New antivirals in hepatitis C (2005) (0)
- Prothrombogenic microvasculature and transplant outcome (2002) (0)
- P959 FACTORS AFFECTING OUTCOMES AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) FOR HEPATOCELLULAR CARCINOMA (HCC) (2014) (0)
- Predictive model to assess risk for coronary artery disease and graft failure in cardiac allograft recipients: an immunocytochemical study (1998) (0)
- Abstract 12787: Impact of Different P2Y12 Inhibitors on Cardiovascular Outcomes in Diabetic versus Non-Diabetic Patients: Insights From Real-World Data (2018) (0)
- P719 INDEPENDENT PREDICTORS OF PATIENT-REPORTED OUTCOMES (PROS) AND QUALITY OF LIFE (QOL) IN CHRONIC HEPATITIS C PATIENTS RECEIVING INTERFERON (IFN)-FREE VERSUS IFN-CONTAINING REGIMENS WITH SOFOSBUVIR (SOF) (2014) (0)
- Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study: 364 (2013) (0)
- The early detection of patients at risk of developing transplant-associated CAD is a major step toward inter- vention with adequate therapies for preventing or miti- gating (2001) (0)
- Novel Inter ferons for Treatment of Hepatitis C Virus (2009) (0)
- 416 LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND TRANSIENT ELASTOGRAPHY IN RELATION TO VIROLOGIC RESPONSE: A SUBSTUDY OF THE PHASE 3 ALBINTERFERON ALFA-2B TRIALS (2010) (0)
- 287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT (2010) (0)
- 483 TRAIL Agonist Resistance is Associated With Death Receptor Mutations (2010) (0)
- Willingness to participate in research among black patients with liver disease: A national cross‐sectional study (2021) (0)
- Phytohaemagglutinin plus anti-CD28 induce conversion of CD4+CD25- T cells into CD4+CD25+ regulatory T cells (47.17) (2009) (0)
- Accelerated coronary artery disease in heart transplant recipients with depleted arteriolar tissue plasminogen activator (1994) (0)
- CARDIAC-SPECIFIC TROPONIN I LEVELS DURING THE FIRST MONTH POST-TRANSPLANT PREDICT CORONARY ARTERY DISEASE IN HEART TRANSPLANT PATIENTS (1999) (0)
- Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection (2022) (0)
- Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial (2022) (0)
- 310 MARKED SPIROMETRY DECLINE IN PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT WITH ALBINTERFERON ALFA-2B IS SIMILAR TO PEGINTERFERON ALFA-2A (2010) (0)
- Mo1919 Chronic Aminotransferase Elevation Confounds Transient Elastography in HCV Patients With Early Stage Fibrosis (2012) (0)
- Barriers to Treatment of Chronic Hepatitis C with Direct Acting Antivirals in an Urban Clinic (2018) (0)
- Successful Treatment with Sofosbuvir (SOF) Regimen Improves Patient-reported Outcomes (PROs) in Patients with Chronic Hepatitis C (CH-C): 482 (2013) (0)
- Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C. (2006) (0)
- P149 Anti-angiotensin ii type 1 receptor antibodies are associated with positive flow crossmatches in heart Transplant Candidates (2018) (0)
- Reply (2012) (0)
- 195 CYCLOSPORINE HELPS TO ACHIEVE A HIGHER SVR IN PATIENTS RECEIVING PEG-INTERFERON/RIBAVIRIN FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: FINAL ANALYSIS OF A RANDOMIZED-CONTROLLED STUDY (2008) (0)
- Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3 (2014) (0)
- Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection. (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David R. Nelson?
David R. Nelson is affiliated with the following schools:
